The impaired IL-17F response but enhanced IL-17A mRNA expression from PBMCs triggered by TLR2 ligands in AD patients may therefore contribute to a more complicated mechanism to the pathogenesis of AD through exacerbating the Th2 response in AD development. The gene discussed is IL17A; the disease is Alzheimer disease.